ArticleFrontiers in immunology2012
Annexin A1 and the regulation of innate and adaptive immunity.
Article in Frontiers in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 174 citations in OpenAlex.
- Neutrophil Extracellular Traps protein composition is specific for patients with Lupus nephritis and includes methyl-oxidized αenolase (methionine sulfoxide 93).Scientific reports · 2019Trial
- Article
- Extracellular matrix microarchitecture modulates cellular behavior and extracellular vesicle phenotypes in biomimetic tendon models.Bioengineering & translational medicine · 2026Article
- Defining the human lung pathodegradome of the V8 protease fromInfection and immunity · 2026Article
- Annexin A1 and Dexamethasone Treatment in Hospitalized COVID-19 Patients: Impact on Disease Recovery and Evidence for an Interplay Between Proresolving Mediators.Biomolecules · 2026Article
- ANXA1-mediated mTOR/FABP4 Inhibition Drives Antifibrotic Macrophage Reprogramming in Lupus Nephritis.International journal of biological sciences · 2026Article
- Fumarate inhibits the formation of neutrophil extracellular traps (NETs) in a Nrf2-controlled and Annexin-A1-dependent manner associated with mitochondrial fusion.Frontiers in immunology · 2026Article
- Monocyte-plasma cell communication characterizes treatment-associated peripheral immune remodeling in Guillain-Barré syndrome.Frontiers in immunology · 2026Article
- The Multifaceted Role of Annexin A1 in Colorectal Cancer: From Molecular Mechanisms to Predictive and Prognostic Implications.Medical sciences (Basel, Switzerland) · 2025Review
- Exploring the therapeutic potential of annexin A1-derived peptide AcMolecular and cellular biochemistry · 2025Article
- Single-Cell Transcriptomic Profiling Reveals a Distinct Monocyte MIF/ANXA1 Signature Associated With Poor Responsiveness to ICS.Allergy, asthma & immunology research · 2025Article
- Article
- Article
- sTPLS: identifying common and specific correlated patterns under multiple biological conditions.Briefings in bioinformatics · 2025Article
- Annexin A1: The dawn of ischemic stroke (Review).Molecular medicine reports · 2025Review
- Article
- Role of the Annexin A protein family in liver diseases: insights and therapeutic opportunities.Frontiers in pharmacology · 2025Review
- Article
- Immunogenic cell death-related signature predicts prognosis and immunotherapy efficacy in bladder cancer.Translational cancer research · 2024Article
- Annexin-A1 short peptide alleviates septic myocardial injury by upregulating SIRT3 and inhibiting myocardial cell apoptosis.Histology and histopathology · 2024Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is the body's way of defending itself against noxious stimuli and pathogens. Under normal circumstances, the body is able to eliminate the insult and subsequently promote the resolution of inflammation and the repair of damaged tissues. The concept of homeostasis is one that not only requires a fine balance between both pro-inflammatory mediators and pro-resolving/anti-inflammatory mediators, but also that this balance occurs in a time and space-specific manner. This review examines annexin A1, an anti-inflammatory protein that, when used as an exogenous therapeutic, has been shown to be very effective in limiting inflammation in a diverse range of experimental models, including myocardial ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this glucocorticoid-inducible protein, along with another anti-inflammatory mediator, lipoxin A(4), is starting to help explain and shape our understanding of the resolution phase of inflammation. In so doing, these molecules are carving the way for innovative drug discovery, based on the stimulation of endogenous pro-resolving pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.